Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Bristol-Myers Squibb
Bristol-Myers Squibb
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Boehringer Ingelheim
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
Hoffmann-La Roche
Jiangsu HengRui Medicine Co., Ltd.
National Cancer Institute (NCI)
Alliance for Clinical Trials in Oncology
Bristol-Myers Squibb
Taiho Oncology, Inc.
Actuate Therapeutics Inc.
NRG Oncology
Verastem, Inc.
Merck Sharp & Dohme LLC
Arcus Biosciences, Inc.
Eli Lilly and Company
Eli Lilly and Company
Boehringer Ingelheim
AstraZeneca
Gilead Sciences
Eli Lilly and Company
Pfizer
AstraZeneca
Revolution Medicines, Inc.
AstraZeneca
Hoffmann-La Roche
University of Chicago
Amgen
Pfizer
H. Lee Moffitt Cancer Center and Research Institute
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
University of Maryland, Baltimore
Merck Sharp & Dohme LLC
BioNTech SE
Massachusetts General Hospital
Wake Forest University Health Sciences
M.D. Anderson Cancer Center
University Medical Center Groningen
Regeneron Pharmaceuticals
Eli Lilly and Company
Cancer Institute and Hospital, Chinese Academy of Medical Sciences